Navigation Links
Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer
Date:10/13/2009

hese efficacy results are similar to those obtained previously with repeated administrations of the 1- and 3-month-formulations of triptorelin.

About Debiopharm Group

Debiopharm Group is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses promising biological and small molecule drug candidates. It develops its products for global registration and maximum commercial potential. Once registered, the products are out-licensed to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed four products with global combined sales of $2.6 billion in 2008.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com

About Ipsen

Ipsen is an innovation-driven global specialty pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,200. Its development strategy is based on a combination of specialty medicine, which is Ipsen's growth driver, in targeted therapeutic areas (oncology, endocrinology, neurology and haematology), and primary care products which contribute significantly to its research financing. The location of its four Research & Development centres (Paris, Boston, Barcelona, London) and its peptide and protein engineering platform give the Group a competitive edge in gaining access to leading university research teams and highly qualified personnel. More than 800 people in R&D are dedicated to the discovery and development of innovative drugs for patien
'/>"/>

SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsens Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent
2. The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection
3. Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
4. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
5. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
6. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
7. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
8. Japanese Cancer Association and Debiopharm Honour Japanese Research
9. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
10. Debiopharm and EPFL Establish an Oncology Chair
11. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... , April 30, 2015 The following is an ... Directors of China Cord Blood Corp (NYSE: CO ) ... committee of the independent directors of China Cord Blood Corp ... offer of $6.40 per share from Golden Meditech Holdings Co ... per share would greatly benefit Golden Med and Mr. Kam, ...
(Date:4/30/2015)... SAN DIEGO , April 30, 2015 /PRNewswire/ ... company engaged in the development of biosimilar therapeutics ... today announced the closing of its previously announced ... common stock at a public offering price of ... full by the underwriters of their option to ...
(Date:4/30/2015)... -- WuXi PharmaTech (Cayman) Inc. ("WuXi" or the "Company") ... services provider, today announced that its board of directors ... 29, 2015, from a consortium (the "Consortium") led by ... and chief executive officer of the Company, and Ally ... (the "Transaction") involving the acquisition of all outstanding shares ...
(Date:4/30/2015)... SureClinical, a leader in cloud-based health science ... SureClinical’s executive team as Chief Financial Officer. ... with over 25 years in leadership roles ranging from ... Morris joins SureClinical from Marrone Bio Innovations (MBI), a ... MBI from its founding in 2006 until 2011, when ...
Breaking Biology Technology:April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 2April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 3April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 4April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 5Pfenex Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 2WuXi PharmaTech Announces Receipt of Proposal 2WuXi PharmaTech Announces Receipt of Proposal 3WuXi PharmaTech Announces Receipt of Proposal 4WuXi PharmaTech Announces Receipt of Proposal 5WuXi PharmaTech Announces Receipt of Proposal 6Julie I. Morris Joins SureClinical as Chief Financial Officer 2
... Inc. (Nasdaq: ONXX ) today announced that ... Forum on Wednesday,October 10 at 11:15 a.m. Pacific ... the presentation at:, http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=ONXX&item_id=1657737 It ... early in order to,register and download any necessary ...
... Pharmaceuticals,Inc. (Nasdaq: CADX ), a biopharmaceutical company ... principally,for use in the hospital setting, announced today ... present the corporate overview on,Wednesday, October 10, 2007 ... Time),during the BIO Investor Forum in San Francisco. ...
... 3 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President,and CEO ... will present a,corporate overview of the Company at ... on Tuesday, October 9 at 9 a.m. The ... Conference Centre from October 7-9,2007. About Oncolytics ...
Cached Biology Technology:Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at BIO Investor Forum 2Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe 2
(Date:4/13/2015)... a leading cloud-based consumer engagement platform that provides trusted ... communities around health and wellness, announced today the launching ... The ... vehicle to receive validated health information from consumers. ... will allow higi,s trusted partners, on a user opt-in ...
(Date:4/8/2015)... 2015  Infinisource, a leading provider of SaaS-based Human ... a leading supplier of biometric identification and security ... most advanced biometrically-enabled time clock, the companies announced ... is setting a bold, new standard for the ... small and mid-size employer. When connected to the ...
(Date:4/2/2015)... , April 2, 2015 At its 2015 ... Lake City , the American College of Medical ... new directors to its Board.  Members of the ACMG ... and for forming and advancing its policies and programs. ... profession. "It,s an eventful time in medical ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
... 7, 2010) -- A tumor,s genetic profile is often ... cancers, but inexplicably, genetically similar leukemias in different patients ... Weill Cornell Medical College researchers believe they may have ... differences between patients with acute myeloid leukemia (AML). ...
... the University of Sheffield have scooped an international award in ... make the production of alternative biofuels more energy efficient. ... use in the production of alternative renewable fuels, to replace ... biofuels currently requires vast amounts of power and when the ...
... The earliest known domestic horses are around 4,600 years ... Ukraine and Kazakhstan. Using this evidence, two different hypotheses ... area over the rest of Eurasia; 2) horse domestication ... different local places. "Previous analysis on mitochondrial DNA ...
Cached Biology News:Researchers discover genetic differences between lethal and treatable forms of leukemia 2Scientists' breakthrough in production of biofuels 2Wild Iberian horses contributed to the origin of the current Iberian domestic stock 2
... marking pen has been designed to provide a thin ... specimen on a slide. This barrier creates the ... the target area on the slide. PAP Pen ... and acetone. It can be removed, if desired, ...
Mouse monoclonal antibody to QDPR - quinoid dihydropteridine reductase...
...
Anti-Conjugated Quinaldic Acid...
Biology Products: